Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma
Brief Summary: The aim of this clinical trial is to assess the effect of treatment with a monoclonal antibody called atezolizumab in patients diagnosed with a type of lung cancer called malignant pleural mesothelioma. The efficacy (whether the treatment works), safety and tolerability (side effects of treatment) of atezolizumab plus bevacizumab in combination with standard chemotherapy versus bevacizumab in combination with standard chemotherapy will be investigated.


Options:
A: Arm Label: Bevacizumab plus chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Pemetrexed, Drug: Bevacizumab | Arm Label: Atezolizumab plus bevacizumab plus chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Pemetrexed, Drug: Bevacizumab, Drug: Atezolizumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Atezolizumab plus bevacizumab plus chemotherapy, Bevacizumab plus chemotherapy | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Atezolizumab plus bevacizumab plus chemotherapy, Bevacizumab plus chemotherapy | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Atezolizumab plus bevacizumab plus chemotherapy, Bevacizumab plus chemotherapy | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Atezolizumab plus bevacizumab plus chemotherapy
B: Arm Label: Experimental Arm: Durvalumab + Chemotherapy, then Durvalumab Maintenance; Type: EXPERIMENTAL; Interventions: Drug: Durvalumab | Arm Label: Control Arm: Chemotherapy, then Observation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Chemotherapy | Arm Label: Control Arm: Ipilimumab and Nivolumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ipilimumab and Nivolumab | Intervention Type: DRUG; Name: Durvalumab; Assigned to Arm(s): Experimental Arm: Durvalumab + Chemotherapy, then Durvalumab Maintenance | Intervention Type: DRUG; Name: Standard Chemotherapy; Assigned to Arm(s): Control Arm: Chemotherapy, then Observation | Intervention Type: DRUG; Name: Ipilimumab and Nivolumab; Assigned to Arm(s): Control Arm: Ipilimumab and Nivolumab
C: Arm Label: Drug: ADI-PEG 20 plus Pem Platinum; Type: EXPERIMENTAL; Interventions: Drug: ADI-PEG 20 plus Pem Platinum | Arm Label: Drug: Placebo plus Pem Platinum; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo plus Pem Platinum | Intervention Type: DRUG; Name: ADI-PEG 20 plus Pem Platinum; Assigned to Arm(s): Drug: ADI-PEG 20 plus Pem Platinum | Intervention Type: OTHER; Name: Placebo plus Pem Platinum; Assigned to Arm(s): Drug: Placebo plus Pem Platinum
D: Arm Label: Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: MEL: Pembrolizumab 10 mg/kg Q2W (Part B); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 2 mg/kg Q3W (Part E-Not Enrolled); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 5 mg/kg Q3W (Part E-Not Enrolled); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 10 mg/kg Q3W (Part E-Not Enrolled); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): MEL: Pembrolizumab 10 mg/kg Q2W (Part B), MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D), MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D), NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F), NSCLC: Pembrolizumab 10 mg/kg Q3W (Part E-Not Enrolled), NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F), NSCLC: Pembrolizumab 2 mg/kg Q3W (Part E-Not Enrolled), NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F), NSCLC: Pembrolizumab 5 mg/kg Q3W (Part E-Not Enrolled), Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A), Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1), Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A), Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2), Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2), Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)

Answer: A